Vanda Pharmaceuticals (STU:VM4) Accumulated other comprehensive income (loss) : €0.4 Mil (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Vanda Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €0.4 Mil.

Vanda Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 (€0.6 Mil) to Dec. 2024 (€0.1 Mil) but then increased from Dec. 2024 (€0.1 Mil) to Mar. 2025 (€0.4 Mil).

Vanda Pharmaceuticals's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 (€-1.1 Mil) to Dec. 2023 (€-0.0 Mil) and increased from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€0.1 Mil).

Vanda Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Vanda Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.20

-0.16

-1.13

-0.03

0.07

Vanda Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.35	-0.31	0.63	0.07	0.35

Vanda Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Vanda Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

VNDA:USA 0LKB:UK VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines